IDEAYA Biosciences
IDYA

$35.29

1.55%

Market Cap: $2.98B

About: IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.

Employees: 124

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

0

Analysts bullish %

of 12 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

44% more repeat investments, than reductions

Existing positions increased: 89 | Existing positions reduced: 62

4.18% more ownership

Funds ownership: 107.02% [Q1] → 111.19% (+4.18%) [Q2]

7% more call options, than puts

Call options by funds: $800K | Put options by funds: $748K

2% less funds holding

Funds holding: 202 [Q1] → 198 (-4) [Q2]

12% less first-time investments, than exits

New positions opened: 29 | Existing positions closed: 33

16% less capital invested

Capital invested by funds: $3.5B [Q1] → $2.95B (-$545M) [Q2]

25% less funds holding in top 10

Funds holding in top 10: 4 [Q1] → 3 (-1) [Q2]

See Fund Rankings

Research analyst outlook

12 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$50

42%

upside

Avg. target

$60

71%

upside

High target

$69

96%

upside

12 analyst ratings

12 positive

100%

0 neutral

0%

0 negative

0%

Stifel Benjamin Burnett 80% 1-year accuracy 4 / 5 met price target	93%upside $68	Buy Maintained	10 Sept 2024
Citigroup Yigal Nochomovitz 45% 1-year accuracy 17 / 38 met price target	64%upside $58	Buy Maintained	27 Aug 2024
JP Morgan Anupam Rama 45% 1-year accuracy 26 / 58 met price target	87%upside $66	Overweight Maintained	8 Aug 2024
RBC Capital Gregory Renza 52% 1-year accuracy 35 / 67 met price target	73%upside $61	Outperform Reiterated	7 Aug 2024
Wedbush Robert Driscoll 55% 1-year accuracy 35 / 64 met price target	53%upside $54	Outperform Reiterated	7 Aug 2024

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about IDYA published over the past 30 days

IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel

Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, Actelion Pharmaceuticals, Eisai, GSK, and the U.S. FDA SOUTH SAN FRANCISCO, Calif. , Sept. 18, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that Douglas B.

IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. , Aug. 30, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on August 29, 2024, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 34,000 shares of the Company's common stock to a newly hired employee.

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif. , Aug. 26, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference.

IDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. , Aug. 23, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on August 19, 2024, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 150,000 shares of the Company's common stock to a newly hired employee.

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

Darovasertib achieves triple-digit enrollment in Phase 2/3 trial in 1L HLA-A2*02:01(-) MUM; and >50 patients enrolled in Phase 2 neoadjuvant UM study ASCO 2024 oral presentation of darovasertib in neoadjuvant UM; FDA Type C meeting for neoadjuvant UM in Q3'24 and targeting Phase 2 neoadjuvant UM data update in H2'24 Demonstrated preliminary proof-of-concept for IDE397 in MTAP urothelial and lung cancer; 1 PR awaiting confirmation has confirmed and 1 additional PR still awaiting confirmation, from the 2 uPRs noted in the July 8, 2024 webcast IDEAYA, in consultation with Amgen, has now financially budgeted to support its obligations for target IDE397 / AMG 193 clinical combination expansion in NSCLC Phase 1 FPI achieved for IDE397 and Trodelvy® combo in MTAP-deletion urothelial cancer Targeting initial IDE161 Ph 1/2 expansion and Phase 1 FPI for IDE161 in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in endometrial cancer in H2'24 Targeting Werner IND in H2'24, and MTAP and KAT6 pathway DCs in H2'24 Targeting B7H3/PTK7 Topo-Payload Bispecific-ADC DC nomination in H2'24 IDEAYA to host an Investor R&D Day in Q4 2024 $952.7 million of cash, cash equivalents and marketable securities as of June 30, 2024, supplemented by net proceeds of $283.8 million from July 2024 public offering, anticipated to fund operations into at least 2028 SOUTH SAN FRANCISCO, Calif. , Aug. 6, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a business update, and announced financial results for the second quarter ended June 30, 2024.

IDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

Zacks Investment Research

IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Should You Buy?

IDEAYA Biosciences (IDYA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Should You Buy?

IDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen

Option for an exclusive worldwide license for potential first-in class B7H3/PTK7 topo-I-payload bispecific antibody drug conjugate (BsADC) program B7H3/PTK7 co-expression found in multiple solid tumor types, including double-digit percent prevalence in lung, colorectal, and head and neck cancers Rational combo opportunities with IDEAYA's DNA Damage Repair (DDR) pipeline, including IDE161 (PARG) Targeting development candidate nomination in H2 2024 SOUTH SAN FRANCISCO, Calif. and BEIJING, China , July 31, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced that it has entered into an option and license agreement for a potential first-in-class B7H3/PTK7 BsADC program with Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

IDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen

Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program

BEIJING, China & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #ADC--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody/ADC therapeutics, announced that it has entered into an option and license agreement for a potential first-in-class B7H3/PTK7 BsADC program with IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics.

Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program

Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program

BEIJING & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody/ADC therapeutics, announced that it has entered into an option and license agreement for a potential first-in-class B7H3/PTK7 BsADC program with IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics. “We are.

Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program

IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event

SOUTH SAN FRANCISCO, Calif. , July 29, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations event.

IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event

See News Rankings